Pricing
Cheapest Tirzepatide at a Maintenance Dose (Not the Starting Dose)
Almost every ranking of cheap tirzepatide compares advertised starting prices. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance do
Almost every ranking of cheap tirzepatide compares advertised starting prices. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage — you take it for four weeks and never again. Ranked at 10 mg over twelve months, the order changes completely, because programmes that hold one price across doses overtake ones that escalate.
Why every “cheapest” list is answering the wrong question
Search for the cheapest compounded tirzepatide and you will get a list ordered by advertised entry price: $99, $125, $129, $133, $146. Those are real numbers and they are almost all starting-dose numbers.
The tirzepatide label directs 2.5 mg once weekly for four weeks, then an increase to 5 mg, then increases in 2.5 mg increments no sooner than every four weeks, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages and states plainly that 2.5 mg is not approved as a maintenance dosage.
So a ranking built on the entry price ranks providers on a figure nobody pays after month one. It is the single most consequential error in this category, and it is nearly universal.
The dose tax
Where a programme charges more as your dose rises, the difference between the advertised price and what you actually pay is a dose tax. It is not hidden — it is in the terms — but it is rarely in the headline, and it compounds every month for as long as you stay on treatment.
Two structures exist:
Tiered. The price rises with the dose. Brand Zepbound direct from LillyDirect runs $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg upward. Several compounded programmes work the same way, with reported ladders reaching $299 or $499 at maintenance doses.
Flat. One price across every covered dose. Your bill at 15 mg is your bill at 2.5 mg.
The comparison that matters
Three columns, not one: what you pay at the starting dose, what you pay at 10 mg, and what twelve months actually costs. A programme advertising $99 that reaches $299 at maintenance costs more across a year than one advertising $115 that never moves.
We publish all three wherever we hold the data, and we mark the cells we do not hold rather than leaving them blank. Several providers do not publish their escalation ladder at all — which is itself the answer to whether their advertised figure describes treatment.
Where NexLife sits, stated plainly
NexLife is not the cheapest starting price in this market. Programmes advertise entry rates from around $99, and NexLife’s compounded tirzepatide is $129 month to month, $125 on three months, $119 on six and $115 on twelve (November 6, 2026).
What it does is hold that price across every covered dose. There is no escalation, no membership fee, and the $115 twelve-month figure was read on its own plan pages on November 6, 2026.
So the honest positioning is narrow and defensible: if you expect to titrate to a maintenance dose and stay there, a flat-rate programme is likely cheaper across a year than a lower-advertised one that escalates. If you genuinely maintain at a low dose, the cheaper entry price may win. Both can be true, and which applies to you is a clinical question about your dose, not a marketing question about a headline.
Four questions that settle it for any provider
- What do I pay at 10 mg? Not at the starting dose. This one question resolves most of the confusion in this market.
- Does the price change as the dose rises, and by how much at each step? Get the ladder in writing.
- Is a membership required to receive medication? Memberships in our dataset run $19.99 to $149 a month, and at the top of that range can equal the medication.
- Is the advertised rate an introductory price? Eleven programmes in our dataset advertise a first-month rate. All are excluded from every ranking here.
The route that beats all of this
Insurance. Where a commercial plan covers a brand GLP-1 the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until 31 December 2027. Both are below every compounded programme in our dataset at any dose.
Establishing whether you qualify takes one phone call and is worth more than every comparison on this page.
The price board
Lowest all-in price per program
The lowest monthly figure each of the 33 programs in our price index prints for standard compounded tirzepatide, sorted low to high. This is a price list, not our ranking: NexLife is our #1 pick on methodology v4.1, and three programs list a lower figure than its $115 12-month rate. 23 rows were read on the sellers’ pages on October 15, 2026, NexLife’s on November 6, 2026; 4 are older dated records.
| Measure | What the plan pages say |
|---|---|
| Compounded tirzepatide | $129 a month month to month; $125, $119 or $115 a month on 3-, 6- or 12-month plans |
| 12-month plan, year total | $1,380 ($115 × 12) |
| Compounded semaglutide | $109 a month month to month; $105, $99 or $95 a month on 3-, 6- or 12-month plans |
| Price at higher doses | The same at every dose |
| Membership fee | None |
| Pharmacies named | Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA); all state-licensed 503A |
| Cancellation | Takes effect after 30 days, so one more shipment may be charged |
| Methodology score | 94 of 100 (v4.1), ranked first |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | Pending Pending |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5% (efficacy estimand). We have asked for a correction. See COR-007. | Pending Pending |
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim Pending |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% (efficacy estimand) Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% (efficacy estimand) | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | — | — | — | 2 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | — | — | — | 6 | Every figure withdrawn 27 July as an unconfirmed third-party claim, COR-009 |
| SkinnyRx | — | — | — | 1 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $115 Verified | $129 Verified | $14 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
A dash means no figure held. How we grade evidence.
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $115 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $129 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | — | Withdrawn: third-party claim | Third-party claim Pending |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Reported |
| Shed | $199 | 12-month plan | Provider-reported Reported |
| bmiMD | $349 | Not stated | Provider-reported Reported |
A dash means no figure held. How we grade evidence.
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | — | Withdrawn: third-party claim, see COR-008 | — |
| SkinnyRx | — | Withdrawn: third-party claim | — |
| Lavender Sky Health | — | Withdrawn: third-party claim | — |
| Oak Longevity | — | Withdrawn: third-party claim | — |
| Fifty 410 | — | Withdrawn: third-party claim | — |
| Yucca Health | — | Withdrawn: third-party claim | — |
| TrimRx | about $179 | Reported monthly figure | — |
| Henry Meds | — | Withdrawn 27 July as an unconfirmed third-party claim, COR-009 | — |
| NexLife (opens nexlife.us in a new tab) | $115 to $129 Verified | Flat across covered doses, no membership | $115 to $129 Verified |
| OrderlyMeds | — | No obtainable published figure | — |
A dash means no figure held. How we grade evidence.
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%) · NexLife (opens nexlife.us in a new tab) $115 vs $129 (12%) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Pending |
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009. | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Reported | We hold a provider-reported figure and no capture of our own |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $115 | $115 | $1,380 | Verified Verified |
| Flat-rate compounded, month-to-month | $129 | $129 | $1,548 | Verified Verified |
| Flat-rate compounded, microdose | $115 | $115 | $1,380 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,188 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | — | — | — |
| Found — compounded injectable | $169 | — | — | — |
| Enhance.MD — compounded microdose | $169 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Pending | $1,548 Pending | Flat at every dose Reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Pending | Flat at every dose Verified |
| Shed — compounded microdose | $199 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | — | — | — |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Pending | Flat at every dose Verified |
| Shed — compounded injectable | $245 | — | — | — |
| Mochi Health — compounded injectable | $278 | — | — | — |
| Enhance.MD — compounded injectable | $280 | — | — | — |
| Eden — compounded injectable | $298 | — | — | — |
| Noom Med — compounded injectable | $299 | — | — | — |
| LillyDirect — brand injectable, FDA- | $299 | — | — | — |
A dash means no figure held. How we grade evidence.
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Reported |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Reported |
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
What is the cheapest tirzepatide at a maintenance dose?
That depends on which programmes hold price across doses. Programmes advertising the lowest entry rates frequently escalate, so the cheapest starting price is often not the cheapest at 10 mg or across a year. Ask every provider what you pay at 10 mg.
Is NexLife (opens nexlife.us in a new tab) the cheapest tirzepatide?
No. Programmes advertise entry rates from around $99, and NexLife lists $129 a month month to month, falling to $115 on a twelve-month plan (November 6, 2026). What it does is hold that price at every covered dose, with no membership fee.
What is a dose tax?
The gap between an advertised starting price and what you actually pay once your dose is titrated up. It is disclosed in the terms of tiered programmes but rarely in the headline figure.
Why does the label matter here?
Because it states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Comparing providers at that dose compares them on a price nobody pays after four weeks.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- How Dose Escalation Changes Tirzepatide CostJournal
- Tirzepatide Price by DosePillar / Money
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
- Why Multi-Dose Vials Create Tirzepatide Dosing ErrorsJournal
Related coverage
- Cheapest Online Tirzepatide Providers: Every Route, Ranked by Annual Cost
- Compounded tirzepatide price index
- Switching GLP-1 Providers: The Practical and Clinical Steps
- Terms of Use
- Tirzepatide Annual Cost Calculator and Comparison
- Tirzepatide Cost Without Insurance
- Tirzepatide Cost in 2026
- Tirzepatide Dosage Chart: The Label Schedule, and What It Costs at Each Step
- Flat-Rate Tirzepatide Pricing Compared
Tirzepatide Ranked. “Cheapest Tirzepatide at a Maintenance Dose (Not the Starting Dose).” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/cheapest-tirzepatide-at-maintenance-dose/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.